Partial Rupture of the Rotator Cuff
Conditions
Interventions
This is a study conducted at a single center, located at UNICAMP Hemocenter, and it is a randomized, prospective, double-blind, and controlled clinical trial. The patients will be randomly assigned to
H02.403.750
Sponsors
Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP
Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP
Eligibility
Age
25 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients of both sexes, aged over 25 years, with partial rupture of the supraspinatus less than or equal to 1 cm in the longitudinal axis evaluated by ultrasound.
Exclusion criteria
Exclusion criteria: Patients who underwent any ultrasound-guided needling procedure in the affected tendon, use of infiltration with corticosteroids in the affected shoulder in the last 6 months, presence of another pathology of the shoulder to be treated (fracture or arthritis of rheumatic origin), cervical spine radiculopathy, pregnancy, neoplasm, severe liver disease or nephropathy, autoimmune, inflammatory or infectious diseases, acute or chronic, hypersensitivity to lidocaine, use of anti-inflammatory drugs or corticosteroids in any form before 6 weeks of application of platelet-rich plasma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: Complete healing of the supraspinatus tendon rupture and improvement in the WORC and SF-36 questionnaire, in the comparison between the PRP and placebo groups.;Found outcome 1: Complete healing of 79.3% of the partial ruptures of the supraspinatus tendon and significant improvement in the WORC questionnaire, in the comparison between the PRP and placebo groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes were not expected | — |
Countries
Brazil
Contacts
Public ContactRenato de Castro
Centro de Hematologia e Hemoterapia - HEMOCENTRO UNICAMP
Outcome results
None listed